Anna Baran

More From Anna Baran

We Raise Our Fair Value for BioNTech Vaccine Profits

We have added the firm's vaccine candidate to our model with a 60% probability of success.

Anna Baran Jul 29, 2020

Pfizer, BioNTech COVID-19 Vaccines Fast Tracked by FDA

We expect no-moat BioNTech and wide-moat Pfizer to move one of the test candidates into the next phase, planned to start as early as this month.

Anna Baran Jul 13, 2020

BioNTech and Pfizer Report Good News From Vaccine Trial

A long road lies ahead as the trial continues, but we are maintaining our fair value estimates for the two healthcare firms.

Anna Baran Jul 1, 2020

All Eyes on BioNTech's COVID-19 Vaccine

But the entire pipeline merits attention.

Anna Baran Jun 26, 2020

An Undervalued but High Uncertainty Biotech Firm

Anna Baran Oct 9, 2019

Intercept Looks to Be First in Lucrative Market

But the pipeline of competing drugs is full, so we don’t see a moat for the biotech.

Anna Baran Jul 19, 2019

Alexion's Rare-Disease Reign Not Over

The biopharma is well positioned with its label expansions and pipeline.

Anna Baran Mar 6, 2019

CROs Poised to Benefit From Biopharma Outsourcing

Of the contract research organizations we cover, Syneos looks most attractively valued.

Anna Baran Jan 11, 2019

More About Anna Baran

Anna Baran is an equity analyst on the healthcare team for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc.

Before joining Morningstar in 2016, Baran completed a research project in oncology at the Feinberg School of Medicine and another research thesis in neurobiology at Northwestern University. Before moving to her current role in February 2018, she was on the global and managed portfolios service teams at Morningstar.

Baran holds a bachelor’s degree in economics and biological sciences from Northwestern University. She is also a Level II candidate in the Chartered Financial Analyst® program.